• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Tamoxifen in advanced male breast cancer.

作者信息

Aisner J, Ross D D, Wiernik P H

出版信息

Arch Intern Med. 1979 Apr;139(4):480-1.

PMID:435005
Abstract

A 47-year-old man with metastatic carcinoma of the breast was found to have positive estrogen and progesterone receptors but refused castration or estrogens. After failing on combination chemotherapy he was started on tamoxifen, which resulted in a partial response lasting seven months. He relapsed in bone and then consented to orchiectomy, which resulted in further clinical improvement. Thus, the tamoxifen did not preclude further hormonal therapy. This case, added to others reported, suggests that tamoxifen may be useful in the treatment of advanced male breast cancer. Further studies are needed to determine the level of activity, when to use the drug, and the predictive value of hormone receptors.

摘要

相似文献

1
Tamoxifen in advanced male breast cancer.
Arch Intern Med. 1979 Apr;139(4):480-1.
2
Tamoxifen therapy in premenopausal women with metastatic breast cancer.
Cancer Treat Rep. 1985 Apr;69(4):363-8.
3
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.TP53基因的全序列分析预示晚期乳腺癌对全身治疗反应不佳。
Cancer Res. 2000 Apr 15;60(8):2155-62.
4
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.新型芳香化酶抑制剂伏罗唑(R83842)用于他莫昔芬治疗后病情进展的绝经后晚期乳腺癌女性患者的II期研究。
Clin Cancer Res. 1995 Mar;1(3):287-94.
5
[A case of advanced breast cancer with multiple organ metastases successfully treated by tamoxifen].[一例晚期乳腺癌伴多器官转移经他莫昔芬成功治疗的病例]
Gan To Kagaku Ryoho. 1992 Nov;19(13):2255-8.
6
Antiestrogen-induced remissions in stage IV breast cancer.抗雌激素诱导的IV期乳腺癌缓解
Cancer Treat Rep. 1976 Oct;60(10):1445-50.
7
Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.利用雌激素受体信息在美国推广乳腺癌辅助多药化疗和他莫昔芬:1975 - 1999年
J Natl Cancer Inst Monogr. 2006(36):7-15. doi: 10.1093/jncimonographs/lgj003.
8
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.一种与原发性乳腺癌中他莫昔芬治疗失败相关的候选分子特征。
Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.
9
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.前列腺特异性抗原(PSA)的表达与复发性乳腺癌对他莫昔芬治疗的不良反应相关。
Br J Cancer. 1999 Feb;79(5-6):888-94. doi: 10.1038/sj.bjc.6690142.
10
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.阿那曲唑与他莫昔芬作为早期雌激素受体阳性乳腺癌患者初始辅助治疗的获益及预期成本效益
Cancer. 2004 Sep 15;101(6):1311-22. doi: 10.1002/cncr.20492.

引用本文的文献

1
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer.表征男性和女性乳腺癌中类固醇激素受体的染色质结合图谱。
Nat Commun. 2018 Feb 2;9(1):482. doi: 10.1038/s41467-018-02856-2.